title: A comparison of the efficacy, safety, and patient satisfaction of ondansetron versus droperidol as antiemetics for elective outpatient surgical procedures. S3A-409 and S3A-410 Study Groups.
abstract: Two identical, randomized, double-blind, placebo-controlled studies enrolled 2061 adult surgical outpatients at high risk of postoperative nausea and vomiting (PONV) to compare i.v. ondansetron 4 mg with droperidol 0.625 mg and droperidol 1.25 mg for the prevention of PONV. The antiemetic drugs or placebo were administered i.v. 20 min before the induction of anesthesia with a barbiturate compound, followed by maintenance with N2O/isoflurane/enflurane. Nausea, emetic episodes, adverse events, and patient satisfaction were analyzed for the 0 to 2 h and 0 to 24 h postoperative periods. In the 0 to 2 h postoperative period, there was a complete response (no emesis or rescue antiemetic) in 46% of subjects given placebo (P < 0.05 versus antiemetic groups), in 62% given ondansetron, in 63% given droperidol 0.625 mg, and in 69% given droperidol 1.25 mg (P < 0.05 versus ondansetron). In the 0 to 24-h postoperative period, there were no significant differences in complete response between the ondansetron and droperidol 0.625 or 1.25 mg groups; all groups remained superior to placebo. The proportion of patients without nausea during the 0 to 24 h postoperative period was greater in the antiemetic groups compared with the placebo group; however, droperidol 1.25 mg was more effective than ondansetron 4 mg or droperidol 0.625 mg (43% vs 29% or 29%, respectively). Headache incidence was higher in the ondansetron group compared with either droperidol group. Patient satisfaction scores did not differ significantly among antiemetic treatment groups, although all were superior to placebo. In conclusion, all antiemetic treatment regimens were superior to placebo for the prevention of PONV in the immediate postoperative period; however, droperidol 1.25 mg was more efficacious than ondansetron during the early recovery period (0-2 h). There were no significant differences between ondansetron and either droperidol dose for emesis prevention during the 0 to 24 h postoperative period.
  
  
  CONCLUSIONS
  More than 2000 patients at high risk of postoperative nausea and vomiting were given either placebo, ondansetron 4 mg, or droperidol 0.625 mg or 1.25 mg i.v. before the administration of general anesthesia. After surgery, the incidence of nausea, vomiting, medication side effects, and patient satisfaction were evaluated for 24 h. Droperidol 0.625 or 1.25 mg i.v. compared favorably with ondansetron 4 mg i.v. for the prevention of postoperative nausea and vomiting after ambulatory surgery.
authors.affiliation: Department of Anesthesiology, Duke University, Durham, North Carolina 27710, USA.
authors.forename: J T
authors.initials: JT
authors.lastname: Fortney
authors.forename: T J
authors.initials: TJ
authors.lastname: Gan
authors.forename: S
authors.initials: S
authors.lastname: Graczyk
authors.forename: B
authors.initials: B
authors.lastname: Wetchler
authors.forename: T
authors.initials: T
authors.lastname: Melson
authors.forename: S
authors.initials: S
authors.lastname: Khalil
authors.forename: R
authors.initials: R
authors.lastname: McKenzie
authors.forename: S
authors.initials: S
authors.lastname: Parrillo
authors.forename: P S
authors.initials: PS
authors.lastname: Glass
authors.forename: C
authors.initials: C
authors.lastname: Moote
authors.forename: D
authors.initials: D
authors.lastname: Wermeling
authors.forename: T V
authors.initials: TV
authors.lastname: Parasuraman
authors.forename: B
authors.initials: B
authors.lastname: Duncan
authors.forename: M R
authors.initials: MR
authors.lastname: Creed
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000556:Ambulatory Surgical Procedures; D000771:Anesthesia, Intravenous; D018685:Anesthetics, Inhalation / Q000008:administration & dosage; D018686:Anesthetics, Intravenous / Q000008:administration & dosage; D000932:Antiemetics / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001463:Barbiturates / Q000008:administration & dosage; D004311:Double-Blind Method; D004329:Droperidol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017558:Elective Surgical Procedures; D005260:Female; D005500:Follow-Up Studies; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000517:prevention & control; D017294:Ondansetron / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017060:Patient Satisfaction; D010919:Placebos; D011183:Postoperative Complications; D011292:Premedication; D012307:Risk Factors; D014839:Vomiting / Q000517:prevention & control
chemical_list: D018685:Anesthetics, Inhalation; D018686:Anesthetics, Intravenous; D000932:Antiemetics; D001463:Barbiturates; D010919:Placebos; D017294:Ondansetron; D004329:Droperidol